Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: Clin Pharmacokinet. 2019 Dec;58(12):1567–1576. doi: 10.1007/s40262-019-00773-1

Table 2.

Population Pharmacokinetic Model Parameters

PK parameter Point Estimates %RSE Bootstrap Median [95% CI]
Fixed
  CL= θ1 × (WT/70)0.75 * θ9INDU
  θ1 (L h−1) 34.6 9.2 34.7 [27.7, 40.9]
  θ9 1.54 10.1 1.54 [1.2, 1.89]
  V1= θ2 × (WT /70)1 θ2 (L) 222 18.6 9.24 [3.72, 13.32]
  Q= θ3 × (WT /70)0.75 θ3 (L h−1) 8.58 18.9 9.24 [3.72, 13.32]
  V2= θ4 × (WT /70)1 θ4 (L) 311 13.1 332 [150, 472]
Interindividual Variability
  ω2CL (%CV) 0.37 (60.7%) 38.2 0.34 [0.07, 0.67]
  ω2V1 (%CV) 1.15 (107.2%) 43.1 1.15 [0.1, 2.2]
COVCL-V1 0.63 (r=0.85) 41.3 0.55 [0.04, 1.22]
Residual Variability*
  Proportional (%CV) 52% 15.4 50.6% [43.3%, 59.7%]
*

Residual Variability was additive in log scale. %CV was calculated by square root of variance x 100. INDU: CYP3A4/5 Inducer.